World’s First Human Stem Cell Clinical Trial Approved by Japanese Government
        
            By Ida Torres, 
                Japan Daily Press
             | 07. 19. 2013
        
                    
                                    
                    
                                                                                                                                    
                                                                            
                              
    
  
  
    
  
          
  
      
    
            The Japanese government finally gave its approval for the world’s first clinical trials using stem cells that will be harvested from the patient’s body. Health Minister Norihisa Tamura gave permission for two research institutes to start their tests to treat age-related macular degeneration (AMD) by using “induced Pluripotent Stem (iPS) cells”.
The Riken Center for Developmental Biology and the Institute of Biomedical Research and Innovation (IBRI) Hospital in Kobe will be doing the joint testing to treat AMD, a condition that usually causes blindness among the elderly. This condition is incurable at the moment, and affects around 700,000 middle-aged to older people in Japan alone. Their proposal was 
approved by a government committee last month, but they had to wait for the Health Ministry to sign off before starting the tests.
Riken will harvest the stem cells from the patients while IBRI will conduct the transplant by the middle of next year. The trial treatment will try 
replacing the damaged part of the eye of six patients who have AMD with the retinal cells that will be created from the...
 
 
  
 
    
    
  
   
                        
                                                                                
                 
                                                    
                            
                                  
    
  
  
      Related Articles
    
  
          
  
  
  
  
  
  
      
            
                  
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Emma Belmonte,  ChinaFile | 10.03.2025
                                                        
     
    
    
            
On the popular Chinese social media platform Xiaohongshu, also known as RedNote, an account called “Georgia Notes” (@格鲁吉亚小纸条) offers tips and advice to Chinese nationals planning a trip to the Republic of Georgia. In one post...
 
       
 
 
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Karin Hammarberg, Alex Polyakov, Catherine Mills, and Karinne Ludlow,  The Conversation | 10.03.2025
                                                        
     
    
    
            Reports of several cases of embryo and sperm mix-ups have put the Australian fertility industry in the spotlight for all the wrong reasons.
These bungles have raised serious questions about the industry’s current model of self-regulation, and demonstrate a lack...
 
       
 
 
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Jared Whitlock,  Endpoints News | 10.09.2025
                                                        
     
    
    
            When Nirnay Murthy learned about a treatment for his toddler son’s rare condition, relief quickly gave way to disappointment.
A one-time gene therapy called Zolgensma from the Swiss drugmaker Novartis can halt spinal muscular atrophy, a deadly condition that causes...
 
       
 
 
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Karin Hammarberg and Catherine Mills,  BioNews | 10.13.2025
                                                        
     
    
    
            
The Australian fertility industry has been rocked by several recent cases of embryo and sperm mix-ups. With a lack of transparency about what clinics do to prevent such errors recurring, trust and confidence in the industry and how it is...